AdaptHealth, LLC -- Moody's assigns Ba3 CFR to AdaptHealth LLC and B1 rating to proposed notes

Rating Action: Moody's assigns Ba3 CFR to AdaptHealth LLC and B1 rating to proposed notes

Global Credit Research - 14 Jul 2020

New York, July 14, 2020 -- Moody's Investors Service ("Moody's") today assigned a first-time Ba3 Corporate Family Rating and Ba3-PD Probability of Default Rating to AdaptHealth LLC, a subsidiary of AdaptHealth Corp (collectively "AdaptHealth"). Moody's also assigned a B1 rating to AdaptHealth's offering of $300 million senior unsecured bonds as well as a SGL-1 Speculative Grade Liquidity rating. The outlook is stable.

Proceeds from the bond offering as well as a new (unrated) $232 million term loan will be used to refinance existing debt, a portion of which was used to fund recent acquisitions. The B1 rating assigned to the senior unsecured bonds reflects their structural subordination to the secured debt in the company's capital structure, comprised of a $175 million (unrated) revolving credit facility and the $232 million term loan. The bonds benefit from loss absorption provided by approximately $144 million of unrated debt issued by AdaptHealth LLC's indirect parent company, which does not have any guarantee from operating entities and is therefore structurally subordinated to the proposed bond.

Ratings assigned:

..Issuer: AdaptHealth, LLC

.... Probability of Default Rating, Assigned Ba3-PD

.... Speculative Grade Liquidity Rating, Assigned SGL-1

.... Corporate Family Rating, Assigned Ba3

....Senior Unsecured Regular Bond/Debenture, Assigned B1 (LGD4)

Outlook Actions: ..Issuer: AdaptHealth, LLC ....Outlook, Assigned Stable RATING RATIONALE

AdaptHealth's Ba3 Corporate Family Rating reflects the company's moderate scale in the provision of home healthcare equipment and related supplies in the United States with pro-forma revenues of approximately $1 billion. The company focusses on a broad range of patient needs including sleep, home medical equipment, diabetes and respiratory products, the majority of which relate to chronic medical conditions with high levels of recurring revenues. AdaptHealth is somewhat concentrated in sleep related products which are approximately 33% of pro forma revenue, as well as a geographic concentration in the New York and middle-Atlantic region. Moody's estimates pro-forma debt/EBITDA is moderately high at approximately 4.8 times on a basis that deducts patient capital expenditures from EBITDA. The ratings are constrained by Moody's expectations AdaptHealth will remain acquisitive.

The outlook is stable. Moody's expects the company will continue to execute a growth strategy that relies on acquisitions, though AdaptHealth will continue its track record of successful acquisition integration. Moody's expects AdaptHealth will maintain moderate leverage, with credit metrics that may temporarily rise because of acquisitions.